Tuberculosis: a new way of improving treatment rejected

In 2003, a new antibiotic from the fluoroquinolone family – gatifoxacin was provided for four months treatment of Tuberculosis, instead of the six months required with the current standard combination therapy. After ten years' worth of tests, the results turned out to be inconclusive. While the new treatment was well-tolerated, it was less effective than the standard regime and the relapse rate over the following months turned out to be twice as high. As a result, the tested combination cannot provide an alternative to the current standard treatment.
Source : www.medicalnewstoday.com      2015/1/28 17:16

خانه چاپ ارسال به دوستان نسخه متنی کوچک کردن متن بزرگ کردن متن دانلود خروجی پی دی اف خروجی میکروسافت ورد
1/10 (تعداد آرا 1 نفر )
Copyright © 2011 AASM. All Rights Reserved.